Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis

Gut

Volumn 40, Issue 4, 1997, Pages 531-535

  Yamaguchi, H ^a   Weidenbach, H ^a   Luhrs H ^a   Lerch, M M ^a   Dickneite, G ^b   Adler, G ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Behring Diagnostics GmbH   (Germany)

Author keywords

Antithrombin III; C1 esterase inhibitor; Coagulation system; Experimental acute pancreatitis; Kallikrein kinin system

Indexed keywords

ALBUMIN; ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; BERINERT; COMPLEMENT COMPONENT C1S INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; MALE; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RAT;

EID: 0030961267     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.4.531     Document Type: Article

References (25)

1. 125I-labeled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBS Lett 1979; 97: 111-5.
2. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462-8.
3. Van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-58.
4. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma protease inhibitors. J Biol Chem 1985; 260: 1723-9.
5. Orfan NA, Kolski GB. Angioedema and C1 inhibitor deficiency. Ann Allergy 1992; 69: 167-72.
6. Bjork I, Danielsson A. Antithrombin and related inhibitors of coagulation proteinases. In: Barrett AJ, Salvesen G, eds. Proteinase inhibitors. Amsterdam: Elsevier, 1986: 489-513.
7. Adler G, Hupp T, Kern HF, Course and spontaneous regression of acute pancreatitis in the rat. Virchows Arch 1979; 383: 32-47.
8. Lerch MM, Weidenbach H, Gress TM, Adler G. Effect of kinin inhibition in experimental acute pancreatitis. Am J Physiol 1995; 269: G490-9.
9. Knot EAR, de Jong E, ten Cate JW, Gie LK, van Royen EA. Antithrombin III: Biodistribution in healthy volunteers. Thromb Haemost 1987; 58: 1008-11.
10. De Smet BJGL, De Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 1993; 81: 56-61.
11. Yamaguchi H, Kimura T, Nawata H. Does stress play a role in the development of severe pancreatitis in rats? Gastroenterology 1990; 98: 1682-8.
12. Lerch MM, Saluja AK, Runzi M, Dawra R, Saluja M, Steer ML. Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum. Gastroenterology 1993; 104: 853-61.
13. Marceau F, Lussier A, Regoli D, Giroud JP. Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol 1983; 14: 209-29.
14. Satake K, Koh I, Nishiwaki H, Umeyama K. Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. Digestion 1985; 32: 99-105.
15. Seung WP, Feldman BF. Early phase components of the kallikrein kinin system in hemorrhagic ascitic fluid and plasma in the rat with induced acute pancreatitis. Am J Vet Res 1985; 46: 1961-6.
16. Ruud TE, Aasen AO, Pillgram-Larsen J, Stadaas JO. Effects on peritoneal proteolysis and hemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis. Scand J Gastroenterol 1986; 21: 1018-24.
17. Vesetini S, Benetti L, Bassi C, Bonora A, Campedelli A, Zamboni G, et al. Effects of choline-esterase inhibitor in experimental acute pancreatitis in rats. Preliminary results. Int J Pancreatol 1993; 13: 217-20.
18. Niederau C, Brinsa R, Niederau M, Lüthen R, Strohmeyer G, Ferrell LD. Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol 1995; 17: 189-96.
19. Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM, Schreuder WO, Felt-Bersma RJF, Abbink JJ, et al. Proteolytic inactivation of plasma C1 inhibitor in sepsis. J Clin Invest 1989; 84: 443-50.
20. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJM, Wagstaff J, Thijs LG. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993; 19: S19-28.
21. Weidenbach H, Lerch MM, Gress TM, Pfaff D, Turi S, Adler G. Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis. Gut 1995; 37: 434-40.
22. Bleeker WK, Agterberg J, Rigter G, Hack CE, Gool JV. Protective effect of antithrombin III in acute experimental pancreatitis in rats. Dig Dis Sci 1992; 37: 280-5.
23. Dickneite G, Páques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 1993; 69: 98-102.
24. Triantaphyllopoulos DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemost 1984; 51: 232-5.
25. Emerson ThE Jr, Fornel WJ, Leach WJ, Redens ThB. Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat. Circ Shock 1987; 21: 1-13.